Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
The Oncologist|May 11, 2026
A Phase I/II Trial of Concurrent Chemo-hormonal Enzalutamide and Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate CancerJulie N Graff, Claire E P Smith, Alexandra O Sokolova, et al.
NPJ Precision Oncology|September 13, 2023
Evolution of structural rearrangements in prostate cancer intracranial metastasesFrancesca Khani, William F Hooper, Xiaofei Wang, et al.
Cancer Research Communications|January 5, 2026
Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer TypesYa-Mei Hu, Faming Zhao, Julie N Graff, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)Fred Saad, Kim N Chi, Neal D Shore, et al.
European Urology|September 10, 2020
Apalutamide and Overall Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
The New England Journal of Medicine|February 9, 2018
Apalutamide Treatment and Metastasis-free Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
Annals of Clinical and Translational Neurology|December 20, 2018
Protein production is an early biomarker for RNA-targeted therapiesWade K Self, Kathleen M Schoch, Jacob Alex, et al.
British Journal of Cancer|November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTANJohn Shen, Simon Chowdhury, Neeraj Agarwal, et al.
Clinical Genitourinary Cancer|June 29, 2017
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate CancerTerence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, et al.
Nature Medicine|October 7, 2025
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trialGerhardt Attard, Neeraj Agarwal, Julie N Graff, et al.
Pageof 8